Pegylated interferon plus ribavirin therapy improves pancreatic -cell function in chronic hepatitis C patients
Posted on Mon, Aug 15, 2011
Pegylated interferon plus ribavirin therapy improves pancreatic -cell function in chronic hepatitis C patients
Liver International, 08/15/2011 Clinical Article
Huang JF et al. – This study demonstrated pancreatic β–cell function was ameliorated by peginterferon plus ribavirin(PegIFN/RBV) therapy in chronic hepatitis C(CHC) patients, particularly in those responders.
Methods
- Total of 277 non–diabetic patients treated with PegIFN–α and weight–based RBV, with 80/80/80 adherence, were recruited.
- Their insulin resistance(IR) and β–cell function by homeostasis model assessment model (HOMA–IR and HOMA–%B) before treatment and at 24 week after treatment [end of follow–up (EOF)] was measured.
Results
- Sustained virological response (SVR) was achieved by 79.4% (220/277) of all patients: 63.6% (75/118) of genotype–1 and 91.2% (145/159) of genotype–non–1 patients.
- There was no significant change of ...read more
Read all
Family Medicine news articles at
MDLinx.com